Literature DB >> 23803174

Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial.

Stacia M Desantis1, Christos Lazaridis, Yuko Palesch, Viswanathan Ramakrishnan.   

Abstract

BACKGROUND: The modified Rankin scale (mRS) is the most common functional outcome assessed in stroke trials. The proportional odds model is commonly used to analyze this ordinal outcome but it requires a restrictive assumption that a single odds ratio applies across the entire outcome scale. AIMS: The study aims to model the effect of tissue-type plasminogen activator on ordinal mRS, test model assumptions, and compare fits and predictive ability of the statistical models.
METHODS: Several ordinal regression methods are presented and applied to a re-analysis of the 1995 NINDS tissue-type plasminogen activator study. Violations of the proportional odds assumption are demonstrated using graphs and statistical tests, and the partial proportional odds model is introduced and recommended as an alternative for the analysis of mRS.
RESULTS: The partial proportional odds model relaxes the assumptions about treatment effect on the ordinal outcome scale and provides a better fit to the data than the commonly used proportional odds model (likelihood ratio test chi-square = 8·05, P = 0·005). It provides easily interpretable odds ratios and it is able to detect efficacy at the lower end and a lack of efficacy at the upper end of the mRS scale. Further, it provides lower prediction error than the proportional odds model (0·002 versus 0·005).
CONCLUSIONS: Assuming proportional odds when it does not hold can mask differential treatment effects at the upper end of the ordinal mRS scale and has implications for reduced power when studies are designed under this assumption.
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization.

Entities:  

Keywords:  clinical trial; modified Rankin scale; ordinal regression; partial proportional odds; proportional odds; tissue plasminogen activator

Mesh:

Substances:

Year:  2013        PMID: 23803174      PMCID: PMC5042689          DOI: 10.1111/ijs.12052

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  21 in total

1.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

2.  Using binary logistic regression models for ordinal data with non-proportional odds.

Authors:  R Bender; U Grouven
Journal:  J Clin Epidemiol       Date:  1998-10       Impact factor: 6.437

3.  Statistical assessment of ordinal outcomes in comparative studies.

Authors:  S C Scott; M S Goldberg; N E Mayo
Journal:  J Clin Epidemiol       Date:  1997-01       Impact factor: 6.437

Review 4.  Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons.

Authors:  M J Campbell; S A Julious; D G Altman
Journal:  BMJ       Date:  1995-10-28

5.  Sample size calculations for ordered categorical data.

Authors:  J Whitehead
Journal:  Stat Med       Date:  1993-12-30       Impact factor: 2.373

6.  Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter?

Authors:  J M Wardlaw; P A Sandercock; C P Warlow; R I Lindley
Journal:  Stroke       Date:  2000-05       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.

Authors:  Hans-Christoph Diener; Kennedy R Lees; Patrick Lyden; Jim Grotta; Antoni Davalos; Stephen M Davis; Ashfaq Shuaib; Tim Ashwood; Warren Wasiewski; Vivian Alderfer; Hans-Goran Hårdemark; Larry Rodichok
Journal:  Stroke       Date:  2008-03-27       Impact factor: 7.914

9.  NXY-059 for acute ischemic stroke.

Authors:  Kennedy R Lees; Justin A Zivin; Tim Ashwood; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; James Grotta; Patrick Lyden; Ashfaq Shuaib; Hans-Göran Hårdemark; Warren W Wasiewski
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes.

Authors:  George Howard; Jennifer L Waller; Jenifer H Voeks; Virginia J Howard; Edward C Jauch; Kennedy R Lees; Fenwick T Nichols; Volker W Rahlfs; David C Hess
Journal:  Stroke       Date:  2012-02-16       Impact factor: 7.914

View more
  6 in total

Review 1.  Alternative clinical trial design in neurocritical care.

Authors:  Christos Lazaridis; Andrew I R Maas; Michael J Souter; Renee H Martin; Randal M Chesnut; Stacia M DeSantis; Gene Sung; Peter D Leroux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2015-06       Impact factor: 3.210

2.  Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  Commun Stat Simul Comput       Date:  2016-09-23       Impact factor: 1.118

3.  Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  J Biopharm Stat       Date:  2018-07-09       Impact factor: 1.051

4.  Analysis of the Modified Rankin Scale in Randomised Controlled Trials of Acute Ischaemic Stroke: A Systematic Review.

Authors:  Aimie Nunn; Philip M Bath; Laura J Gray
Journal:  Stroke Res Treat       Date:  2016-03-20

5.  Repeated Measures of Modified Rankin Scale Scores to Assess Functional Recovery From Stroke: AFFINITY Study Findings.

Authors:  Alexander Chye; Maree L Hackett; Graeme J Hankey; Erik Lundström; Osvaldo P Almeida; John Gommans; Martin Dennis; Stephen Jan; Gillian E Mead; Andrew H Ford; Christopher Etherton Beer; Leon Flicker; Candice Delcourt; Laurent Billot; Craig S Anderson; Katharina Stibrant Sunnerhagen; Qilong Yi; Severine Bompoint; Thang Huy Nguyen; Thomas Lung
Journal:  J Am Heart Assoc       Date:  2022-08-05       Impact factor: 6.106

6.  Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.